Sbi pharma fund direct
WebApr 13, 2024 · Now invest in SBI Healthcare Opportunities Fund at Moneycontrol.com. English. ... Pharma Industry Conclave Unlocking opportunities in Metal and ... Axis … WebOn the basis of market research and investor’s financial objective, the asset manager allocates the funds to different assets. For example, a debt-oriented would invest just 20% in equity-oriented funds to keep the risk levels low. However, an equity-oriented fund would invest more than 70% in equity and rest in debt.
Sbi pharma fund direct
Did you know?
WebApr 13, 2024 · Portfolio of SBI Healthcare Opportunities Fund - Direct Plan This fund's portfolio is largely conservative. This fund’s holdings are mostly in Large Cap stocks and … Web22.39%. View performance details. 1.34 lakh people have invested in this fund as of Mar 10, 2024. Invest. Fund summary Portfolio Performance Fund details. This is an Equity Sectoral/Thematic, Pharma fund with S&P BSE HEALTHCARE (TRI) as its benchmark. The risk level for this fund is categorized as Very High Risk. Total AUM.
WebApr 13, 2024 · SBI Healthcare Opportunities Fund Direct Plan-Growth has ₹1,575 Crores worth of assets under management (AUM) as on 31/12/2024 and is medium-sized fund of … WebSBI Healthcare Opportunities Fund Direct Plan-Growth Fund Details. Investment Objective - The scheme seeks to provide the investors with the opportunity of long-term capital …
WebApr 13, 2024 · SBI Healthcare Opportunities Fund Direct Plan-Growth Equity Pharma Min. Investment ₹ 500 Category Returns 17.76 % 27.11 % 3Y Returns 24.66 About DSP Healthcare Fund Direct - Growth DSP Healthcare Fund Direct - Growth is a Equity mutual fund scheme from DSP Mutual Fund. WebFind basic information about the Sbi Healthcare Opportunities Fund Direct Growth mutual fund such as total assets, risk rating, Min. investment, market cap and category. Learn …
WebIn the last 1 year, SBI Healthcare Opportunities Fund Direct Growth has given -1.24% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 4.38% In the last 3 years, DSP Healthcare Fund Direct Growth has given 27.2% return, outperforming Nippon India Pharma Fund - Direct Plan - Growth Plan by 2.73% per annum
WebSBI Technology Opportunities Fund - Regular Plan - Growth Regular Direct Category : Sectoral/Thematic Fund House : SBI Mutual Fund Snapshot Returns Analysis Portfolio SIP Calculator... is bosnia a developing countryWebApr 13, 2024 · About SBI Healthcare Opportunities Fund. SBI Healthcare Opportunities Fund-Growth is a Sectoral-Pharma mutual fund scheme from Sbi Mutual Fund Sectoral-pharma funds charge. SBI Healthcare Opportunities Fund-Growth returns of last 1-year are -0.44%. Since launch, it has delivered 15.19% average annual returns. The fund has … is bosnia and herzegovina part of natoWebSBI Healthcare Opportunities Fund Direct Growth ₹244.04 SBI_HEAL_OPPO_1GATWIY0.50% Aditya Birla Sun Life Digital India Fund Direct Plan Growth ₹130.52 ADIT_BSL_DIGI_TBK8LK0.77% ICICI... is bosnia and herzegovina in european unionWebYou may invest in their mutual funds by following this step-by-step guide. Step 1: Visit the Groww website from your browser. Existing members can simply log in, while new users need to do a one-time registration. Step 2: Submit documents that prove your identity. is bosnia and herzegovina the same countryWebSBI Healthcare Opportunities Fund-Growth Fund Key Highlights 1. Current NAV: The Current Net Asset Value of the SBI Healthcare Opportunities Fund as of Mar 10, 2024 is Rs 214.41 for Growth option of its Regular plan. 2. Returns: Its trailing returns over different time periods are: -6.69% (1yr), 26.42% (3yr), 11.63% (5yr) and 15.42% (since launch). is bosnia a part of natoWebApr 13, 2024 · SBI Healthcare Opportunities Fund Direct Plan-Growth as of 27 Feb 2024, 04:00 PM ₹ 1,574.52 Cr Scheme Asset Size Fund Type Open-End Exit Load Exit load of … is bosnia and herzegovina safe to travelWebApr 13, 2024 · Tata India Pharma & HealthCare Fund Direct-Growth has ₹486 Crores worth of assets under management (AUM) as on 31/12/2024 and is medium-sized fund of its category. The fund has an expense ratio of 1.01%, which is less than what most other Sectoral-pharma funds charge. is bosnia in europe or asia